PRAEMIUM LIMITED — Share Issue/Capital Change 2011

Sep 13, 2011

14 September 2011

Appendix 3B

In accordance with the requirements of the Listing Rules, Praemium Limited (ASX:PPS) releases the attached Appendix 3B in respect to issues made under the Praemium Directors & Employees Benefits Scheme.

About Praemium: Praemium Ltd (ASX:PPS) is one of Australia's leading suppliers of online financial portfolio administration and Separately Managed Account (SMA) technology, administering in excess of AUD 45billion-FUA* of assets in Australia and with more than £280million-UK* in funds on the platforms (FOP) it operates in the UK. Praemium currently provides services to approximately 500* financial institutions and intermediaries, including some of the world's largest financial institutions.

*As at 30 June 2011

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of entity

Praemium Limited

ABN

74 098 405 826

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1+Class of +securities issued or tobe issued	1.Ordinary Shares2.Performance Rights3.Options
2of +securities issued orNumbertobeissued(ifknown)ormaximum number which may beissued	1480,000 Ordinary Shares2.5,500,000 Performance Rights3.1,000,000 Options

+ See chapter 19 for defined terms.

3	Principal terms of the +securities(eg, if options, exercise price andexpirydate;ifpartlypaid+securities,theamountoutstanding and due dates for+convertiblepayment;ifsecurities, the conversion priceand dates for conversion)	1.Fully paid ordinary shares issued to UKKey Management Personnel pursuantto Praemium Employee & DirectorsBenefits Plan.2.Performance Rights capable of vestingon achieving performance criteria linkedtoEBITpersharerelatingtothefollowing performance periods:•250,000 – FY12:•2,625,000 – FY13;•1,375,000 – FY14; and•1,250,000 – FY153.Options with an exercise price thatVaries depending on exercise date -15cents from 10/8/13 to 9/8/14, 25centsifexercisedbetween10/8/14and9/8/15,and35centsifexercisedbetween 10/8/15 and 9/8/16.
4	Do the +securities rank equally inall respects from the date ofallotment with an existing +classof quoted +securities?If the additional securities do notrank equally, please state:•the date from which they do•theextenttowhichtheyparticipateforthenextdividend, (in the case of atrust, distribution) or interestpayment•the extent to which they donot rank equally, other than inrelation to the next dividend,distributionorinterestpayment	1.Yes. The new ordinary shares willrank equally with the existing ordinaryshares on issue traded under tickercode PPS.2.The ordinary shares, if any, to beissued on achieving the performancecriteria, will rank equally with existingordinary shares.3.The ordinary shares, if any, to beissued on payment of the exerciseprice, will rank equally with existingordinary shares.
5	Issue price or consideration	Nil.
6	Purpose of the issue(If issued as consideration for theacquisitionofassets,clearlyidentify those assets)	Shares, performance rights and options wereissued as an incentive / reward to employeepursuant to Praemium Directors & EmployeeBenefits Plan;
7	Dates of entering +securitiesinto uncertificated holdings ordespatch of certificates	9 September 2011

+ See chapter 19 for defined terms.

	Number	+Class
8+classNumberandof+securitiesquotedon(includingthesecuritiesclause 2 if applicable)	242,871,611allASXin	242,391,611- existing fully paidordinary shares, plus480,000 new fully paidordinary shares issuedon exercise of optionat $0.155

		Number	+Class
9	+classNumberandofall+securities not quoted on ASX(includingthesecuritiesinclause 2 if applicable)	13,882,285	Performance Rights &Options (see detailedtable attached asattachment A)
10	Dividend policy (in the case of atrust, distribution policy) on theincreased capital (interests)	No change in dividend policy

+ See chapter 19 for defined terms.

Part 2 - Bonus issue or pro rata issue

11	Issecurityholderapprovalrequired?
12	Is the issue renounceable ornon-renounceable?
13	Ratio in which the +securitieswill be offered
14	+Class of +securities to whichthe offer relates
15	+Recorddatetodetermineentitlements
16	Willholdingsondifferentregisters (or subregisters) beaggregatedforcalculatingentitlements?
17	Policy for deciding entitlementsin relation to fractions
18	Names of countries in which theentity has +security holders whowillnotbesentnewissuedocuments
	Note: Security holders must betold how their entitlements are tobe dealt with.
	Cross reference: rule 7.7.
19	Closingdateforreceiptofacceptances or renunciations
	Names of any underwriters
21	Amount of any underwriting feeor commission
22	Names of any brokers to theissue
23	Fee or commission payable tothebroker to the issue

+ See chapter 19 for defined terms.

• Appendix 3B Page 5 1/1/2003

• 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on

• 25 If the issue is contingent on +security holders' approval, the date of the meeting

behalf of +security holders

• 26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled
• 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
• 28 Date rights trading will begin (if applicable)
• 29 Date rights trading will end (if applicable)
• 30 How do +security holders sell their entitlements in full through a broker?
• 31 How do +security holders sell part of their entitlements through a broker and accept for the balance?
• 32 How do +security holders dispose of their entitlements (except by sale through a broker)?

33 +Despatch date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

• 34 Type of securities (tick one)
• (a) Securities described in Part 1
• (b) All other securities

• See chapter 19 for defined terms.

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

• 35 If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders
• 36 If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
• 37 A copy of any trust deed for the additional +securities

Entities that have ticked box 34(b)

38		Number of securities for which
		+quotation is sought

39 Class of +securities for which quotation is sought

+ See chapter 19 for defined terms.

40 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?

If the additional securities do not rank equally, please state:

• the date from which they do
• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
• 41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another security, clearly identify that other security)

	Number	+Class
42+classNumberandofall+securitiesquotedonASX(including the securities in clause38)

+ See chapter 19 for defined terms.

Quotation agreement

• 1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
• 2 We warrant the following to ASX.
  • The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  • There is no reason why those +securities should not be granted +quotation.
  • An offer of the + securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

• Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
• If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
• 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
• 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

(Company secretary)

Sign here: Date: 14 September 2011

Print name: Cathryn Nolan

== == == == ==

+ See chapter 19 for defined terms.

Attachment A Part 1, Question 9

ESP Cdeo	(iptioll isd pheloy&DeAEmnttotscrnsueursuapeefitsland ahe's ADirBePCoGMinectt torsneapprovempany)2008d aded aheAGMin2009t tanmen	IssDateue	iryExpDate	IssuePrice	Noonistreger29Mharc2011(dafteolas)t 3B	/iredExplledCance//Lapdsefailure tostve	/dVestedExercise	llocatiAons	isteNoReongrbe9Setemonpr(f2011Dateohis)3Bt
ESOSAUS	$bleforbeOptiorci0.35cirin30Der 2011ns– exesaexpgcem	//31122008	//31122011	$0.350	62286,				62286,
ESOSAUS	$bleforbeOptiorci0.155irin30Setemns– exesaexpgpr2011	//15032010	//30092011	$0.155	820,000				820,000
ESOSUK	$forOptiorcible0.165irin30Sebetemns– exesaexpprg2011	//31122009	//30092011	$0.165	440,000				440,000
PPSUOPT	$bleforOptiorci1.67 eirin07Au2011stns– exesaxpggu	//13032008	//7082011	$1.670	135,000	135,000			0
SOPPPT	Optioarible erciicededindaftens– vaxeseprpeng ono////frofrci- 15ce10813981425intstontsexesemce,////frcidben 10814d 9815d 35ceitwntsexeseeean, an////dbed 9rcin 10815816twexeseeean	//9911	//982016	$/0,15$/0.25$0.35				000,0001,	000,0001,
	ionlsOTotta				1,457,286	135,000		1,000,000	2,322,286
	p
	PerfoRightsilisericeThe2rmancenexercpranc--ire/ve/10/11st30exp	/10/203010	/10/203011	nil	950,000				950,000
	PerfoRightsilisericeThe3rmancenexercpranc--ire/ve30/10/12stexp	30/10/2010	30/10/2012	nil	950,000				950,000
	PerfoRightsilisericeThe5rmancenexercpranc--ire/ve30/10/11stexp	29/10/2010	30/10/2011	nil	50000,				50000,
	PerfoRightsilisericeThe6rmancenexercpranc--ire/ve30/10/11stexp	1/06/2010	30/10/2011	nil	50000,				50000,
	PerfoRightsilisericeThe7Armancenexercpranc--ire/ve30/10/11stexp	29/10/2010	30/10/2011	nil	100000,				100000,
	PerfoRightsilisericeThe7Brmancenexercpranc--ire/ve30/10/12stexp	29/10/2010	30/10/2012	nil	100000,				100000,

ESP Cdeo	(iptioll isd pheloy&DeAEmnttotscrnsueursuapeefitsland ahe's ADirBePCoGMinectt torsneapprovempany)2008d aded aheAGMin2009t tanmen	IssDateue	iryExpDate	IssuePrice	Noonistreger29Mharc2011(dafteolas)t 3B	/iredExplledCance//Lapdsefailure tostve	/dVestedExercise	llocatiAons	isteNoReongrbe9Setemonpr(f2011Dateohis)3Bt
	PerfoRightsilisericeThe8Armancenexercpranc--ire/ve30/10/11stexp	14/12/2010	30/10/2011	nil	125000,				125000,
	PerfoRightsilisericeThe8Brmancenexercpranc--ire/ve30/10/12stexp	14/12/2010	30/10/2012	nil	125000,				125000,
	OpPerforights(EMIion(UK)) -il eisericetrmancesnxercpTrahe9- EliesVeDa(bjisfacionftstteecttoattncarsusoforndition)6/4/10permancecos	23/12/2010	1/12/2020	nil	1,336,668				1,336,668
	Perforights(EMIOpion(UK)) -il eisericetrmancesnxercpTrahe- EliesVeDa(bjisfacionf10tstteecttottncarsusaoforndition)30/10/11permancecos	23/12/2010	1/12/2020	nil	1,136668,				1,136668,
	Perforights(EMIOpion(UK)) -il eisericetrmancesnxercpfacfTrahe11- EliesVeDa(bjisiontstteecttottncarsusaoforndition)/10/1130permancecos	/12/202310	1/12/2020	nil	1,136663,				1,136663,
	PerfoRights(CFOT1) –nil eisericeVestrmancexercpon–daf isf FY13Anl re(bjisfacionfteortecttottosue onuapsusaoforndition)permancecos	/9/119	/9/1130	Nil				250,000	250,000
	PerfoRights(CFOT2) –nil eisericeVestrmancexercpon–daf isf FY14 Al re(bjisfacionfteortecttottosue onnuapsusaoforndition)permancecos	/9/119	/9/1230	Nil				125000,	125000,
	PerfoRights(CEOT1) –nil eisericeVestrmancexercpon–daf isf FY14 Al re(bjisfacionfteortecttottosue onnuapsusaoforndition)permancecos	9/9/11	30/9/12	Nil				2,500,000	2,500,000

• See chapter 19 for defined terms.

Attachment A Part 1, Question 9

ESP Cdeo	(iptioAll isd pheloy&DenttotEmscrnsueursuapeefitsland ahe's ADirBePCoGMinectt torsneapprovempanyhe)2008d aded aAGMin2009t tanmen	IssDateue	iryExpDate	IssuePrice	Noonistregerh29Marc2011(dafteolas)t 3B	/iredExplledCance//Lapdsefailure tostve	/VedstedExercise	Allocations	isteNoReongrbe9Setemonpr(f2011Dateohis)3Bt
	PerfoRights(CFOT3) –nil eisericeVestrmancexercpon–daf isf FY15Anl re(bjisfacionfteortecttottosue onuapsusaoforndition)permancecos	/9/119	/9/1330	Nil				125000,	125000,
	PerfoRights(CEOT2) –nil eisericeVestrmancexercpon–daf isf FY15Anl re(bjisfacionfteortecttottosue onuapsusaoforndition)permancecos	9/9/11	30/9/13	Nil				1,250,000	1,250,000
	COPerfoRights(ET2) –nil eisericeVestrmancexercpon–daf isf FY16Anl re(bjisfacionfteortecttottosue onuapsusaoforndition)permancecos	9/9/11	30/9/14	Nil				1,250,000	1,250,000
	for()PeRightsincludingEMI OionTols:ttarmanceps				6,059,999			5,500,000	11559,999,
	bef sitiesisshaNutt atmr oecuronuerenodotequ				7,617,285	135,00	0	6,500,00	013882,285,